Review article: Anti-adhesion therapies for inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 6, 2014, Pages 579-594

  Lobaton T ^a   Vermeire, S ^a   Van Assche, G ^a   Rutgeerts, P ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADDRESSIN; AJM 300; ALICAFORSEN; ALPHA4 BETA7 INTEGRIN; ALPHAE BETA7 INTEGRIN; AMG 181; C REACTIVE PROTEIN; CALGRANULIN; CCX 282 B; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CCR9; ETROLIZUMAB; FENYRAMIDOL; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PF 00547659; PLACEBO; UNCLASSIFIED DRUG; VEDOLIZUMAB; VERCIRNON; VERY LATE ACTIVATION ANTIGEN 4;

ABDOMINAL PAIN; ADAPTIVE IMMUNITY; ANUS DISEASE; ARTHRALGIA; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COLITIS; CONCENTRATION RESPONSE; CROHN DISEASE; DEATH; DENDRITIC CELL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; EFFECTOR CELL; ENTEROPATHY; EPITHELIUM CELL; EVENING DOSAGE; FATIGUE; HEADACHE; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; INTESTINE; LUNG EMBOLISM; LYMPHOCYTE COUNT; LYMPHOCYTE HOMING; MEMORY T LYMPHOCYTE; MOLECULAR MECHANICS; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; RESPIRATORY FAILURE; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; CELL ADHESION MOLECULES; COLITIS, ULCERATIVE; HUMANS; INFLAMMATORY BOWEL DISEASES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84894589499     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12639     Document Type: Review

References (121)

1. Ricart E, Panaccione R, Loftus EV, et al,. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004; 10: 207-14.
2. Baumgart DC, Carding SR,. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369: 1627-40.
3. Williams C, Panaccione R, Ghosh S, Rioux K,. Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol 2011; 4: 237-48.
4. Lim WC, Hanauer S,. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev 2010; 12: CD008870.
5. Dignass A, Van Assche G, Lindsay JO, et al,. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
6. Dignass A, Lindsay JO, Sturm A, et al,. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030.
7. Wahed M, Louis-Auguste JR, Baxter LM, et al,. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2009; 30: 614-20.
8. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD,. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121-5.
9. Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH,. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol 2008; 103: 937-43.
10. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
11. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
12. Colombel JF, Sandborn WJ, Rutgeerts P, et al,. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
13. Sandborn WJ, Colombel JF, D'Haens G, et al,. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37: 204-13.
14. Sandborn WJ, Feagan BG, Stoinov S, et al,. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-38.
15. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al,. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-50.
16. Sandborn WJ, Feagan BG, Marano C, et al,. Subcutaneous Golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85-95.
17. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P,. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis Am J Gastroenterol 2011; 106: 644-59.
18. No authors listed. Adalimumab in the treatment of moderate-to-severe ulcerative colitis: ULTRA 2 trial results. Gastroenterol Hepatol (N Y) 2013; 9: 317-20.
19. Ben-Horin S, Chowers Y,. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011; 33: 987-95.
20. Baert F, Noman M, Vermeire S, et al,. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
21. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P,. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-31.
22. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P,. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24.
23. Peyrin-Biroulet L, Lémann M,. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 870-9.
24. Sandborn WJ, Rutgeerts P, Enns R, et al,. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38.
25. Singh JA, Wells GA, Christensen R, et al,. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; 2: CD008794.
26. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V,. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
27. Lichtenstein GR, Feagan BG, Cohen RD, et al,. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
28. ™ registry. Am J Gastroenterol 2012; 107: 1409-22.
29. Beaugerie L, Brousse N, Bouvier AM, et al,. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
30. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD,. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8: 268-74.
31. Wolters FL, Russel MG, Stockbrügger RW,. Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Aliment Pharmacol Ther 2004; 20: 483-96.
32. Langholz E, Munkholm P, Davidsen M, Binder V,. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11.
33. Kaplan GG, Seow CH, Ghosh S, et al,. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol 2012; 107: 1879-87.
34. Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA,. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011; 60: 930-6.
35. Sandborn WJ, Gasink C, Gao LL, et al,. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: 1519-28.
36. ClinicalTrials.gov. Long-term study of CP-690,550 in subjects with ulcerative colitis (OCTAVE). NCT01470612, 2014. Available at: http://clinicaltrials.gov/show/NCT01470612. Accessed January 7, 2014.
37. ClinicalTrials.gov. The safety and efficacy of maintenance therapy with CP-690,550. NCT01393899, 2014. Available at: http://clinicaltrials.gov/show/ NCT01393899. Accessed January 7, 2014.
38. Van Assche G, Rutgeerts P,. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005; 288: G169-74.
39. Thomas S, Baumgart DC,. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology 2012; 20: 1-18.
40. Von Andrian UH, Mackay CR,. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000; 343: 1020-34.
41. Vestweber D, Blanks JE,. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 1999; 79: 181-213.
42. Lawrence MB, Springer TA,. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell 1991; 65: 859-73.
43. Hynes RO,. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-87.
44. Marlin SD, Springer TA,. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 1987; 51: 813-19.
45. Panés J, Granger DN,. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 1998; 114: 1066-90.
46. Elices MJ, Osborn L, Takada Y, et al,. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990; 60: 577-84.
47. Tsuzuki Y, Miura S, Suematsu M, et al,. Alpha 4 integrin plays a critical role in early stages of T lymphocyte migration in Peyer's patches of rats. Int Immunol 1996; 8: 287-95.
48. Hu MC, Crowe DT, Weissman IL, Holzmann B,. Cloning and expression of mouse integrin beta p(beta 7): a functional role in Peyer's patch-specific lymphocyte homing. Proc Natl Acad Sci U S A 1992; 89: 8254-8.
49. Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ,. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4 + T cells. J Immunol 1997; 158: 2099-106.
50. Cepek KL, Parker CM, Madara JL, Brenner MB,. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol 1993; 150: 3459-70.
51. Elewaut D, Van Damme N, De Keyser F, et al,. Altered expression of alpha E beta 7 integrin on intra-epithelial and lamina propria lymphocytes in patients with Crohn's disease. Acta Gastroenterol Belg 1998; 61: 288-94.
52. Oshitani N, Watanabe K, Maeda K, et al,. Differential expression of homing receptor CD103 on lamina propria lymphocytes and association of CD103 with epithelial adhesion molecules in inflammatory bowel disease. Int J Mol Med 2003; 12: 715-19.
53. Schön MP, Arya A, Murphy EA, et al,. Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice. J Immunol 1999; 162: 6641-9.
54. Bernstein CN, Sargent M, Gallatin WM,. Beta2 integrin/ICAM expression in Crohn's disease. Clin Immunol Immunopathol 1998; 86: 147-60.
55. Meenan J, Spaans J, Grool TA, Pals ST, Tytgat GN, van Deventer SJ,. Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation. Gut 1997; 40: 241-6.
56. Biancheri P, Di Sabatino A, Rovedatti L, et al,. Effect of tumor necrosis factor-α blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease. Inflamm Bowel Dis 2013; 19: 259-64.
57. Baert FJ, D'Haens GR, Peeters M, et al,. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22-8.
58. Hogaboam CM, Snider DP, Collins SM,. Activation of T lymphocytes by syngeneic murine intestinal smooth muscle cells. Gastroenterology 1996; 110: 1456-66.
59. Bridges LC, Tani PH, Hanson KR, Roberts CM, Judkins MB, Bowditch RD,. The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin alpha4beta1. J Biol Chem 2002; 277: 3784-92.
60. Li Z, Calzada MJ, Sipes JM, et al,. Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol 2002; 157: 509-19.
61. Bayless KJ, Davis GE,. Identification of dual alpha 4beta1 integrin binding sites within a 38 amino acid domain in the N-terminal thrombin fragment of human osteopontin. J Biol Chem 2001; 276: 13483-9.
62. Salmi M, Andrew DP, Butcher EC, Jalkanen S,. Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms. J Exp Med 1995; 181: 137-49.
63. Eksteen B, Miles AE, Grant AJ, Adams DH,. Lymphocyte homing in the pathogenesis of extra-intestinal manifestations of inflammatory bowel disease. Clin Med 2004; 4: 173-80.
64. Grant AJ, Lalor PF, Hübscher SG, Briskin M, Adams DH,. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 2001; 33: 1065-72.
65. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N,. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-6.
66. Polman CH, O'Connor PW, Havrdova E, et al,. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
67. Rudick RA, Stuart WH, Calabresi PA, et al,. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-23.
68. Gordon FH, Lai CW, Hamilton MI, et al,. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001; 121: 268-74.
69. Ghosh S, Goldin E, Gordon FH, et al,. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348: 24-32.
70. Sandborn WJ, Colombel JF, Enns R, et al,. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-25.
71. Targan SR, Feagan BG, Fedorak RN, et al,. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-83.
72. Gordon FH, Hamilton MI, Donoghue S, et al,. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002; 16: 699-705.
73. Del Pilar Martin M, Cravens PD, Winger R, et al,. Decrease in the numbers of dendritic cells and CD4 + T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008; 65: 1596-603.
74. Bloomgren G, Richman S, Hotermans C, et al,. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-80.
75. Yousry TA, Major EO, Ryschkewitsch C, et al,. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-33.
76. Feagan BG, McDonald J, Greenberg G, et al,. An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis. Gastroenterology 2000; 118: A874.
77. Feagan BG, Greenberg GR, Wild G, et al,. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352: 2499-507.
78. Feagan BG, Greenberg GR, Wild G, et al,. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6: 1370-7.
79. Parikh A, Leach T, Wyant T, et al,. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012; 18: 1470-9.
80. Parikh A, Fox I, Leach T, et al,. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 1691-9.
81. Feagan BG, Rutgeerts P, Sands BE, et al,. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710.
82. Sandborn WJ, Feagan BG, Rutgeerts P, et al,. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711-21.
83. ClinicalTrials.gov. Study of Vedolizumab in patients with moderate to severe Crohn's disease (GEMINI III). NCT01224171; 2013. Available at: http://clinicaltrials.gov/show/NCT01224171. Accessed November 26, 2013.
84. Sands B, Feagan B, Rutgeerts P, et al,. Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind, multicentre trial. J Crohns Colitis 2013; 7 (Suppl. 1): S5-6.
85. Sands B, Hanauer S, Colombel JF,. Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab. 21st United European Gastroenterology Week (UEGWEEK2013), 2013, contribution P887; 2013.
86. ClinicalTrials.gov. A Phase 3, Open-label study to determine the long-term safety and efficacy of Vedolizumab (MLN0002) in patients with ulcerative colitis and Crohn's disease. NCT00790933. Available at: http://clinicaltrials.gov/showNCT00790933. Accessed November 26, 2013.
87. Colombel JF, Sands B, Feagan BG, et al,. Integrated safety analysis of Vedolizumab for the treatment of ulcerative colitis or Crohn's disease. DDW 2013. Gastroenterology 2013; 144 (Suppl. 1): S-113.
88. Pan WJ, Hsu H, Rees WA, et al,. Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells. Br J Pharmacol 2013; 169: 51-68.
89. Pan WJ, Sullivan B, Rees W, et al,. Clinical pharmacology and safety of AMG 181, a human anti-α4β7 antibody for treating inflammatory bowel diseases. 21st United European Gastroenterology Week (UEGWEEK2013), 2013, contribution P914; 2013.
90. Pan WJ, Radford-Smith G, Andrews J, et al,. Safety, pharmacology, and effect of AMG 181, a human anti-α4β7 antibody, in subjects with mild to moderate ulcerative colitis. 21st United European Gastroenterology Week (UEGWEEK2013) 2013, contribution OP264; 2013.
91. ClinicalTrials.gov. Study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 181; 2013. NCT01290042. Available at: http://clinicaltrials.gov/ct2/show/NCT01290042?term=amg181&rank=1. Accessed November 26, 2013.
92. ClinicalTrials.gov. A Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 181 in healthy subjects and subjects with mild to moderate ulcerative colitis; 2013. NCT01164904. Available at: http://clinicaltrials.gov/ct2/show/NCT01164904?term= amg181&rank=2. Accessed November 26, 2013.
93. ClinicalTrials.gov. AMG 181 Phase 2 study in subjects with moderate to severe ulcerative colitis. NCT01694485. Available at: http://clinicaltrials.gov/ ct2/show?term=amg181&rank=3. Accessed November 16, 2013.
94. ClinicalTrials.gov. AMG 181 in subjects with moderate to severe Crohn's disease. NCT01696396. Available at: http://clinicaltrials.gov/show/NCT01696396. Accessed November 26, 2013.
95. Stefanich EG, Danilenko DM, Wang H, et al,. A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol 2011; 162: 1855-70.
96. Rutgeerts PJ, Fedorak RN, Hommes DW, et al,. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Gut 2013; 62: 1122-30.
97. Vermeire S, O'Byrne S, Williams S, et al,. Differentiation between etrolizumab (Rhumab Beta7) and placebo in the eucalyptus Phase II randomized double-blind placebo-controlled induction study to evaluate efficacy and safety in patients with refractory moderate-to-severely active ulcerative colitis. Digestive Diseases Week 2013. Gastroenterology 2013; 144 (Suppl. 1): S-36.
98. ClinicalTrials.gov. Study to evaluate the long-term safety of rhuMAb beta7 in patients with moderate to severe ulcerative colitis. NCT01461317. Available at: http://clinicaltrials.gov/show/NCT01461317. Accessed December 10, 2013.
99. Farkas S, Hornung M, Sattler C, et al,. Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis. Int J Colorectal Dis 2006; 21: 71-8.
100. Vermeire S, Ghosh S, Panes J, et al,. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 2011; 60: 1068-75.
101. ClinicalTrials.gov. A study to monitor long-term treatment with PF-00547659 (OPERA II). NCT01298492. Available at: http://clinicaltrials.gov/ show/NCT01298492. Accessed November 26, 2013.
102. ClinicalTrials.gov. Long-term safety of PF-00547659 in ulcerative colitis (TURANDOT II). NCT01771809. Available at: http://clinicaltrials.gov/show/ NCT01771809. Accessed November 26, 2013.
103. ClinicalTrials.gov. A study of PF-00547659 in patients with moderate to severe ulcerative colitis (TURANDOT). NCT01620255. Available at: http://clinicaltrials.gov/show/NCT01620255. Accessed November 26, 2013.
104. ClinicalTrials.gov. Study to test whether PF-00547659 is safe and improves disease symptoms in patients with Crohn's disease (OPERA). NCT01276509. Available at: http://clinicaltrials.gov/show/NCT01276509. Accessed November 26, 2013.
105. Sugiura T, Kageyama S, Andou A, et al,. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis 2013; 7: e533-42.
106. Takazoe M, Watanabe M, Kawaguchi T, et al,. Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 136 (Suppl. 1): A-181.
107. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al,. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998; 114: 1133-42.
108. Yacyshyn BR, Chey WY, Goff J, et al,. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002; 51: 30-6.
109. Schreiber S, Nikolaus S, Malchow H, et al,. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001; 120: 1339-46.
110. Van Deventer SJ, Tami JA, Wedel MK,. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004; 53: 1646-51.
111. Miner PB, Geary RS, Matson J, et al,. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1427-34.
112. Ghosh S, Panaccione R,. Anti-adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol 2010; 3: 239-58.
113. Rivera-Nieves J, Ho J, Bamias G, et al,. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology 2006; 131: 1518-29.
114. Walters MJ, Wang Y, Lai N, et al,. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2010; 335: 61-9.
115. Keshav S, Vaňásek T, Niv Y, et al,. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS ONE 2013; 8: e60094.
116. ClinicalTrials.gov. An active treatment study to induce clinical response and/or remission with GSK1605786A in subjects with Crohn's disease (SHIELD-4). NCT01536418. Available at: http://clinicaltrials.gov/show/NCT01536418. Accessed November 26, 2013.
117. Van Assche G, Dignass A, Reinisch W, et al,. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010; 4: 63-101.
118. Biancone L, Michetti P, Travis S, et al,. European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohns Colitis 2008; 2: 63-92.
119. Van Damme N, Elewaut D, Baeten D, et al,. Gut mucosal T cell lines from ankylosing spondylitis patients are enriched with alphaEbeta7 integrin. Clin Exp Rheumatol 2001; 19: 681-7.
120. Demetter P, Baeten D, De Keyser F, et al,. Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex. Ann Rheum Dis 2000; 59: 211-16.
121. Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH,. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002; 359: 150-7.